# Clinical Trials Data KRAS - Document 20

# Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients

## Clinical Trial: https://clinicaltrials.gov/study/NCT00964457

"eligibilityCriteria": "Inclusion Criteria:\n\n\* advanced rectum cancer\n\nExclusion Criteria:\n\n\* prior radiation",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided clinical trial information, there are no specific inclusion or exclusion criteria listed concerning KRAS gene mutations. The eligibility criteria you provided include having advanced rectum cancer and no prior radiation treatment. To determine if a patient with a KRAS gene mutation would be eligible, you would need to verify if there are any additional criteria that were not shared.   
  
As it stands with the given information, a KRAS gene mutation does not automatically exclude a patient from participating. However, it is always important to review the full eligibility criteria from the trial documentation and consult with the trial coordinators for confirmation.